The Bcl-2 homology domain 3 (BH3) mimetic ABT-737 reveals the dynamic regulation of bad, a proapoptotic protein of the Bcl-2 family, by Bcl-xL

Molecular Pharmacology

Volumn 79, Issue 6, 2011, Pages 997-1004

  Ezzoukhry, Zakaria ^a,b   Louandre, Christophe ^a   François, Catherine ^c   Saidak, Zuzana ^b   Godin, Corinne ^a,b   Mazière, Jean Claude ^a,b   Galmiche, Antoine ^a,b  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^c UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BH3 PROTEIN; PROTEIN BAD; PROTEIN BCL 2; PROTEIN BCL XL; RECOMBINANT EPIDERMAL GROWTH FACTOR;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PROCESSING; PROTEIN STABILITY; REGULATORY MECHANISM; RNA INTERFERENCE;

BIPHENYL COMPOUNDS; BLOTTING, WESTERN; CELL LINE; CYTOSOL; HUMANS; MOLECULAR MIMICRY; NITROPHENOLS; PIPERAZINES; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE; SULFONAMIDES;

EID: 79956308547     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.070565     Document Type: Article

References (40)

1. Adams KW and Cooper GM (2007) Rapid turnover of mcl-1 couples translation to cell survival and apoptosis. J Biol Chem 282:6192-6200. (Pubitemid 47100899)
2. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, and Letai A (2006) Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9:351-365. (Pubitemid 43668734)
3. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM, and Huang DC (2005) Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17:393-403. (Pubitemid 40193310)
4. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, and Green DR (2010) The BCL-2 family reunion. Mol Cell 37:299-310.
5. Cragg MS, Jansen ES, Cook M, Harris C, Strasser A, and Scott CL (2008) Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest 118:3651-3659.
6. Cragg MS, Harris C, Strasser A, and Scott CL (2009) Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat Rev Cancer 9:321-326.
7. Czabotar PE, Lee EF, van Delft MF, Day CL, Smith BJ, Huang DC, Fairlie WD, Hinds MG, and Colman PM (2007) Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc Natl Acad Sci USA 104:6217-6222. (Pubitemid 47186075)
8. Danial NN (2008) BAD: undertaker by night, candyman by day. Oncogene 27 (Suppl 1):S53-S70.
9. Datta SR, Katsov A, Hu L, Petros A, Fesik SW, Yaffe MB, and Greenberg ME (2000) 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Mol Cell 6:41-51.
10. Ewings KE, Hadfield-Moorhouse K, Wiggins CM, Wickenden JA, Balmanno K, Gilley R, Degenhardt K, White E, and Cook SJ (2007) ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL. EMBO J 26:2856-2867. (Pubitemid 46975775)
11. Frenzel A, Grespi F, Chmelewskij W, and Villunger A (2009) Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis 14:584-596.
12. Fueller J, Becker M, Sienerth AR, Fischer A, Hotz C, and Galmiche A (2008) C-RAF activation promotes BAD poly-ubiquitylation and turn-over by the proteasome. Biochem Biophys Res Commun 370:552-556.
13. Galmiche A, Fueller J, Santel A, Krohne G, Wittig I, Doye A, Rolando M, Flatau G, Lemichez E, and Rapp UR (2008) Isoform-specific interaction of C-RAF with mitochondria. J Biol Chem 283:14857-14866.
14. Galmiche A, Ezzoukhry Z, François C, Louandre C, Sabbagh C, Nguyen-Khac E, Descamps V, Trouillet N, Godin C, Regimbeau JM, et al. (2010) BAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinoma. Mol Cancer Res 8:1116-1125.
15. Hanahan D and Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70. (Pubitemid 30046295)
16. Hekman M, Albert S, Galmiche A, Rennefahrt UE, Fueller J, Fischer A, Puehringer D, Wiese S, and Rapp UR (2006) Reversible membrane interaction of BAD requires two C-terminal lipid binding domains in conjunction with 14-3-3 protein binding. J Biol Chem 281:17321-17336.
17. Hikita H, Takehara T, Shimizu S, Kodama T, Shigekawa M, Iwase K, Hosui A, Miyagi T, Tatsumi T, Ishida H, et al. (2010) The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. Hepatology 52:1310-1321.
18. Hinds MG, Smits C, Fredericks-Short R, Risk JM, Bailey M, Huang DC, and Day CL (2007) Bim, Bad and Bmf: intrinsically unstructured BH3-only proteins that undergo a localized conformational change upon binding to prosurvival Bcl-2 targets. Cell Death Differ 14:128-136.
19. Jeong SY, Gaume B, Lee YJ, Hsu YT, Ryu SW, Yoon SH, and Youle RJ (2004) Bcl-x(L) sequesters its C-terminal membrane anchor in soluble, cytosolic homodimers. EMBO J 23:2146-2155.
20. Kelekar A, Chang BS, Harlan JE, Fesik SW, and Thompson CB (1997) Bad is a BH3 domain-containing protein that forms an inactivating dimer with Bcl-XL. Mol Cell Biol 17:7040-7046. (Pubitemid 27505933)
21. Kim H, Rafiuddin-Shah M, Tu HC, Jeffers JR, Zambetti GP, Hsieh JJ, and Cheng EH (2006) Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 8:1348-1358. (Pubitemid 44835109)
22. Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR, and Newmeyer DD (2005) BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 17:525-535. (Pubitemid 40269117)
23. Lee EF, Czabotar PE, Smith BJ, Deshayes K, Zobel K, Colman PM, and Fairlie WD (2007) Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family. Cell Death Differ 14:1711-1713. (Pubitemid 47278856)
24. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, and Korsmeyer SJ (2002) Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2(3):183-192. (Pubitemid 41043974)
25. Letai AG (2008) Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 8:121-132.
26. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677-681. (Pubitemid 40825512)
27. Petros AM, Nettesheim DG, Wang Y, Olejniczak ET, Meadows RP, Mack J, Swift K, Matayoshi ED, Zhang H, Thompson CB, et al. (2000) Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci 9:2528-2534. (Pubitemid 32105735)
28. Rahmani M, Davis EM, Bauer C, Dent P, and Grant S (2005) Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem 280:35217-35227. (Pubitemid 41532709)
29. Rolando M, Stefani C, Flatau G, Auberger P, Mettouchi A, Mhlanga M, Rapp U, Galmiche A, and Lemichez E (2010) Transcriptome dysregulation by anthrax lethal toxin plays a key role in induction of human endothelial cell cytotoxicity. Cell Microbiol 12:891-905.
30. Scheid MP, Schubert KM, and Duronio V (1999) Regulation of Bad phosphorylation and association with Bcl-x(L) by the MAPK/Erk kinase. J Biol Chem 274:31108-31113. (Pubitemid 29503956)
31. She QB, Solit DB, Ye Q, O'Reilly KE, Lobo J, and Rosen N (2005) The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 8:287-297.
32. Takehara T, Liu X, Fujimoto J, Friedman SL, and Takahashi H (2001) Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology 34:55-61. (Pubitemid 32591483)
33. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, et al. (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10:389-399. (Pubitemid 44711953)
34. Vogler M, Dinsdale D, Dyer MJ, and Cohen GM (2009) Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ 16:360-367.
35. Wang HG, Rapp UR, and Reed JC (1996) Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 87:629-638. (Pubitemid 26386937)
36. Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM, Croce CM, Alnemri ES, and Huang Z (2000) Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 97:7124-7129. (Pubitemid 30431428)
37. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, and Korsmeyer SJ (1995) Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 80:285-291.
38. Yip KW and Reed JC (2008) Bcl-2 family proteins and cancer. Oncogene 27:6398-6406.
39. Youle RJ and Strasser A (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9:47-59.
40. Zha J, Harada H, Yang E, Jockel J, and Korsmeyer SJ (1996) Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87:619-628.